725 results about "Docetaxel" patented technology

A lyophilized solid composition of taxane (preferably docetaxel and paclitaxel), is suitable to prepare a pharmaceutical formulation to be administered to mammals, particularly humans, comprising a taxane, a tensoactive, a lyophilizing excipient, and acid; also essentially free from organic solvents. The solid composition is free from polysorbate 80 and polyoxyethylated castor oil; it is sterile; it is soluble in aqueous solutions in the absence of organic solvent and it has an apparent density from 0.05 g/ml to 0.45 g/ml. A procedure of double lyophilization obtains a solid composition of taxane. A pharmaceutical formulation of a taxane comprises a solid composition of lyophilized taxane and a solubilizing composition. A kit comprises the compositions and a syringe.

Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble polymer such as poly-glutamic acid, poly-aspartic acid or poly-lysine. Also disclosed are methods of using the compositions for treatment of tumors, auto-immune disorders such as rheumatoid arthritis. Other embodiments include the coating of implantable stents for prevention of restenosis.

The present invention relates to a pharmaceutical cocktail, in particular, effective amounts of gemcitabine, in combination with effective amounts of docetaxel and angiogenesis inhibitor, especially a vascular endothelial growth factor (VEGF) inhibitor, such as bevacizumab for the treatment of cancer, in particular sarcoma, especially soft tissue sarcoma. Pharmaceutical compositions and methods of treating cancer, including sarcoma, especially soft tissue sarcoma (prolonging the patient's life, eliminating the tumor, improving the patient's quality of life, shrinking the tumor, prolonging survival and/or preventing the tumor's metastases) are additional aspects of the present invention.

A group of new compounds, N-(all-trans-Retinoyl)-L-cysteic acid, N-(13-cis-Retinoyl)-L-cysteic acid, N-(all-trans-Retinoyl)-L-cysteinesulfinic acid, N-(13-cis-Retinoyl)-L-cysteinesulfinic acid, N-(all-trans-Retinoyl)-L-homocysteic acid, N-(13-cis-Retinoyl)-L-homocysteic acid, and sodium salts of these compounds, including sodium salts of their esters and amides, is shown to exhibit therapeutic effects per se, and which compounds in combination with cytotoxic compounds, such as docetaxel, paclitaxel, doxorubicin and mitoxantrone, exhibit a synergistic effect. These compounds make it possible to manufacture new formulations of poorly soluble pharmaceutical compounds, and the present invention discloses a process of manufacturing water-soluble formulations of such compounds, exemplified by docetaxel, and paclitaxel, exhibiting enhanced pharmacological activity, and formulations of water-soluble pharmaceuticals exemplified by doxorubicin and mitoxantrone, exhibiting improved therapeutic efficacy.

The present invention provides methods and compositions for treating non-small-cell lung cancer (NSCLC) by administering a) a composition comprising nanoparticles that comprise paclitaxel and an albumin and b) a platinum-based agent (e.g., carboplatin). The present application also provides methods of treating prostate cancer by administering to the individual a) an effective amount of a composition comprising nanoparticles comprising docetaxel and an albumin; and b) an effective amount of a steroid.

The invention provides a human antibody that binds human CSF-1R with high affinity. Antibodies of the present invention have significant advantages over the antibodies known in the art by being multifunctional: inhibiting signaling of CSF-1R, internalizing and inducing CSF-1R degradation and stimulating ADCC in cell including tumors, macrophages and monocytes. They are also shown to be effective in treating leukemia, breast, endometrial and prostate cancer alone or in combination with docetaxel, paclitaxel, Herceptin® or doxorubicin.

The invention relates to polymeric micelle medicine carrying system taking amino acid as stabilizing agent and a preparation method thereof. The medicine carrying system can be acted as a medicine carrying composition which is composed of amphipathy block copolymer and amino acid; wherein the amphipathy block copolymer comprises diblock copolymer and triblock copolymer, amino acid is selected from twenty common amino acids, the ratio (w/w) of amphipathy block copolymer and amino acid is 100-1.00: 0.01-99.9.

The present invention provides vitamin E succinate (VES)-stabilized compositions, methods for the preparation thereof and methods useful for the in vivo delivery of substantially water insoluble and optionally chemically unstable pharmacologically active agents (such as docetaxel).

Pharmaceutical formulations comprising docetaxel, solubilizer, and α-lipoic acid, wherein the formulation is substantially free of polysorbates and polyethoxylated castor oil. The solubilizer may comprise glycofurol, acetic acid, benzyl alcohol, or ethanol. The α-lipoic acid, at certain concentrations, may impart stability and prevent degradation of docetaxel while the formulations are in storage. The formulations may be combined with a diluent, which comprises one or more hydrotropes such as tocopherol polyethylene glycol succinate and polyethylene glycol. The formulations combined with the diluent also exhibit stability after storage. Methods of administering docetaxel comprise preparing the formulation comprising docetaxel, solubilizer, and α-lipoic acid; mixing the formulation with a diluent; diluting the resulting formulation in saline, water for injection, or the like; and then injecting the formulations into patients in need thereof.

The present invention relates to a new method of adjuvant therapy in the treatment of early breast cancer, comprising administering six cycles of docetaxel, doxorubicin and cyclophosphamide to a patient in need thereof, wherein said dosages have a marked therapeutic effect when compared to other adjuvant therapies.

The present invention relates to a stable pharmaceutical composition for injection containing docetaxel and a method of preparing the same. More particularly, the present invention relates to a pharmaceutical composition for injection containing docetaxel having better storage stability than conventional medications, which is prepared by dissolving docetaxel, a water-insoluble compound, in distilled water after mixing it with cyclodextrin (CD) and a water-soluble polymer such as hydroxypropyl methylcellulose (HPMC), polyethylene glycol (PEG) or polyvinylpyrrolidone (PVP) and lyophilizing the mixture, and a method of preparing the same.

The invention relates to drug-loading nano-micelles, and a preparation method and an application thereof. According to the to drug-loading nano-micelles, a polyethylene glycol derivative-polylysine-polyleucine amphiphilic triblock copolymer is adopted as a carrier, and self-assembly is carried out in a water solution, such that nano-micelles with a three-layer structure transferring gene and medicine are formed. With the hydrophobic effect between polyleucine, the copolymer forms a core of the micelles in water, such that a hydrophobic medicine docetaxel is entrapped. With polylysine, the nano-micelles are positively charged, such that negatively charged anti-apoptotic protein small interfering RNA can be bonded. Polyethylene glycol is used for protecting the stability of the nano-micelles loading the medicines and gene, and a cycle time of the nano-micelles in vivo is prolonged. The nano-micelles are used for loading both an anti-apoptotic protein small interfering RNA gene medicine and a docetaxel medicine, such that the gene treatment medicine and the chemotherapeutic medicine cooperates in treating cancer, and a synergetic effect of the two medicines can be developed. Therefore, a direction is provided for better treatment of breast cancer.

The present invention relates to an infatmul containing docetaxel and its preparation method. Said preparation can be directly used for intravenous injection. At the same time of that it is used as medicine for curing tumor disease said preparation also can provide nutrients for patient. The weight volume concentration range of docetaxel contained by said preparation is 0.1-1.0 mg/ml, and its specification is that 1-500 mg of active component docetaxel is contained. Said infatmul composition includes docetaxel, vegetable oil, phospholipids and injection water, at the same time the components of glycerin and group emulsion, etc. can be added, in which the optimum group emulsion is poloxamer 188. Besides, said invention also provides the concrete steps of its preparation method and its application in preparation of medicine for resisting tumor.

The invention relates to methods and kits for the prediction of a likely outcome of chemotherapy in a cancer patient. More specifically, the invention relates to the prediction of tumour response to chemotherapy based on measurements of expression levels of a small set of marker genes. The set of marker genes is useful for the identification of breast cancer subtypes responsive to taxane based chemotherapy, such as e.g. a taxane-anthracycline-cyclophosphamide-based (e.g. Taxotere (docetaxel)-Adriamycin (doxorubicin)-cyclophosphamide, i.e. (TAC)-based) chemotherapy.

The invention discloses long-circulating solid lipid docetaxel nanoparticles and a preparation method thereof. The long-circulating solid lipid docetaxel nanoparticles comprise the following materialsin therapeutic effective dose: docetaxel, lipid materials, long-circulating auxiliary materials and an emulsifier. The long-circulating solid lipid docetaxel nanoparticles have small particle size, high encapsulation rate and good stability, and not only improve the solubility and the stability of the docetaxel, reduce the toxicity of the docetaxel, but also prolong the circulating time of a medicament in blood, and improve the therapeutic index of the medicament, so that the preparation has the characteristics of low toxicity, low allergy, high efficiency and targeting in clinical application.

The invention belongs to the field of medicine preparation and particularly relates to a docetaxel solid lipid nanoparticle and a preparation method thereof. The docetaxel solid lipid nanoparticle consists of an effective curative dose of docetaxel, solid lipid materials, liquid lipid materials, an emulsifying agent, additives, long-circulating auxiliary materials and water for injection. The docetaxel solid lipid nanoparticle provided by the invention has the characteristics of stable docetaxel structure, phagocytosis prevention of an in-vivo reticuloendothelial system and active tumor targeting, and can be stably stored.

The invention discloses a mesoporous silica nano-preparation. The mesoporous silica nano-preparation comprises docetaxel or 8-hydroxyquinoline, mesoporous silica nanoparticles, and a lipid double-molecule layer. The mesoporous silica nanoparticles carry docetaxel or 8-hydroxyquinoline. The surfaces of the mesoporous silica nanoparticles carrying docetaxel or 8-hydroxyquinoline are coated with the lipid double-molecule layer. The invention also discloses a preparation method and a use of the mesoporous silica nano-preparation. The mesoporous silica nano-preparation carrying docetaxel or 8-hydroxyquinoline can substantially improve antitumor activity of a drug, can effectively reduce tumor recurrence and nonspecific toxicity and has a very wide application prospect.

The invention relates to the technical field of medicine, which is a preparation of a taxane drug for intravenous drug delivery, consisting of two parts of drug solution and an emulsion. The drug solution is composed of paclitaxel or docetaxel, a pH regulator and a solvent for injection, wherein, the solvent for injection is an organic solvent; the emulsion comprises a fat emulsion and is composed of oil for injection, an emulsifier, an antioxidant, an isotonic regulator, a stabilizer, a pH regulator and water for injection. When in use, the drug solution can be added and evenly mixed in the emulsion for direct intravenous drip according to the clinical drug dosage and can also be firstly added in the emulsion with the volume that is not less than 5 times of the volume of the drug solution according to the clinical drug dosage and then added with a certain amount of physiological saline or glucose injection for intravenous drip. The preparation of the invention does not contain solubilizer and has the advantages of little toxicity, safety, effectivity, stability and economy. The fat emulsion can also be taken as a nutrition replenisher for a patient, thus achieving better treatment effects. The physiological saline or the glucose injection can also replace a certain amount of the emulsion, so the storage and the transportation are convenient, and the preparation is more economical.